Charles Schwab’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Charles Schwab’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-111	Closed	-$27K	–	3594
2021 Q4	$27K	Hold	111	–	–	﹤0.01%	3562
2021 Q3	$48K	Sell	111 -815	-88%	-$53.3K	﹤0.01%	3456
2021 Q2	$506K	Sell	926 -500	-35%	-$31.3K	﹤0.01%	3165
2021 Q1	$558K	Buy	1,426 +161	+13%	+$12.1K	﹤0.01%	3037
2020 Q4	$542K	Sell	1,265 -88	-7%	-$6K	﹤0.01%	2962
2020 Q3	$1.15M	Buy	1,353 +426	+46%	+$48.7K	﹤0.01%	2640
2020 Q2	$767K	Buy	927 +164	+21%	+$13.7K	﹤0.01%	2702
2020 Q1	$284K	Buy	763 +10	+1%	+$713	﹤0.01%	2911
2019 Q4	$287K	Sell	753 -51	-6%	-$4.76K	﹤0.01%	2984
2019 Q3	$1.36M	Buy	804 +92	+13%	+$19.9K	﹤0.01%	2494
2019 Q2	$1.14M	Buy	+712	New	+$202K	﹤0.01%	2535

Other funds holding KRSA

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Charles Schwab's KRSA Position: Q1 2022 in Review

Charles Schwab sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q1 2022, closing a stake of 111 shares — an estimated $27K sold.

Charles Schwab first reported a position in KRSA in Q2 2019 and held it in 11 quarters. The position peaked at $1.36M in Q3 2019. 46 funds tracked by Wall St. Rank hold KRSA as of Q1 2022.

Charles Schwab reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Charles Schwab sold 111 Korsana Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $27K.
Charles Schwab first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 11 quarters.
Charles Schwab's Korsana Biosciences, Inc. Common Stock position peaked at $1.36M in Q3 2019.
46 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.